CareCloud (NASDAQ:CCLD) Cut to Buy at Wall Street Zen

Key Points

• Wall Street Zen downgraded CareCloud (NASDAQ:CCLD) from a “strong-buy” to a “buy”, while MarketBeat’s consensus remains a “Hold” with an average price target of $3.25.
• CareCloud reported quarterly EPS of $0.11, meeting estimates, and set FY2026 guidance of 0.20–0.23 EPS (analysts expect ~0.38 EPS for the current year).
• Shares opened at $3.05 (market cap ≈ $129.6M) trading near its 50/200-day moving averages of ~$3.00, and several institutions including Essex, Hillsdale and Renaissance have recently increased positions, with institutional ownership around 10.16%.

CareCloud (NASDAQ:CCLD - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of CareCloud in a research note on Friday, March 27th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $3.25.

CareCloud Stock Up 1.3%

Shares of NASDAQ CCLD opened at $3.05 on Friday. The firm has a market capitalization of $129.60 million, a PE ratio of 38.13 and a beta of 1.83. The company has a current ratio of 1.05, a quick ratio of 1.03 and a debt-to-equity ratio of 0.01. CareCloud has a 1 year low of $1.56 and a 1 year high of $4.01. The firm's 50-day moving average is $3.00 and its 200-day moving average is $3.01.

CareCloud (NASDAQ:CCLD - Get Free Report) last issued its earnings results on Thursday, March 12th. The company reported $0.11 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.11. CareCloud had a net margin of 8.96% and a return on equity of 24.58%. CareCloud has set its FY 2026 guidance at 0.200-0.23 EPS. Equities analysts expect that CareCloud will post 0.38 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CCLD. Essex Investment Management Co. LLC bought a new position in CareCloud during the 4th quarter worth approximately $2,000,000. Hillsdale Investment Management Inc. boosted its stake in CareCloud by 409.5% during the 3rd quarter. Hillsdale Investment Management Inc. now owns 666,871 shares of the company's stock worth $2,141,000 after acquiring an additional 535,971 shares during the last quarter. Geode Capital Management LLC boosted its stake in CareCloud by 235.4% during the 2nd quarter. Geode Capital Management LLC now owns 359,486 shares of the company's stock worth $848,000 after acquiring an additional 252,299 shares during the last quarter. Legato Capital Management LLC bought a new position in CareCloud during the 4th quarter worth approximately $647,000. Finally, Renaissance Technologies LLC boosted its stake in CareCloud by 96.1% during the 4th quarter. Renaissance Technologies LLC now owns 446,030 shares of the company's stock worth $1,302,000 after acquiring an additional 218,530 shares during the last quarter. Institutional investors own 10.16% of the company's stock.

CareCloud Company Profile

CareCloud, Inc is a healthcare technology company that provides cloud-based practice management, electronic health record (EHR) and revenue cycle management (RCM) solutions to medical practices and health systems. Its flagship offering, the CareCloud Central platform, combines clinical, financial and administrative workflows into a single, unified system. The platform includes modules for scheduling, billing, coding, patient engagement and telehealth, enabling practices to streamline front- and back-office operations and improve overall practice performance.

Founded in 2009 and headquartered in Miami Beach, Florida, CareCloud serves small to mid-size physician groups and specialty clinics across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.